Abstract:Background & Aims:
This study aimed to evaluate quarterly trends in process and health outcomes among Veterans with cirrhosis and assess the factors associated with cirrhosis outcomes before and during the COVID-19 pandemic.
Approach & Results:
US Veterans with cirrhosis were identified using the Veterans Health Administration Corporate Data Warehouse. Quarterly measures were evaluated from September 30, 2018, through March 31, 2022, including twice yearly screening for hepatocellular carcinoma (HCC-6), new … Show more
“…Most clinicians reported that patients with cirrhosis often missed appointments and HCC surveillance was delayed due to limitations of in-person visits. These observations confirm existing reports and concerns about the long-term outcomes of delays in cirrhosis care following onset of the COVID-19 pandemic . However, even more concerning, among survey respondents in the current study, it is clear that despite being over 3 years post onset of the pandemic, the disruptions in cirrhosis care and HCC surveillance in particular remain, and most respondents do not have an effective mechanism to track and re-engage patients who missed HCC surveillance during the pandemic.…”
Section: Discussionsupporting
confidence: 74%
“…These observations confirm existing reports and concerns about the long-term outcomes of delays in cirrhosis care following onset of the COVID-19 pandemic. [33][34][35] However, even more concerning, among survey respondents in the current study, it is clear that despite being over 3 years post onset of the pandemic, the disruptions in cirrhosis care and HCC surveillance in particular remain, and most respondents do not have an effective mechanism to track and re-engage patients who missed HCC surveillance during the pandemic. This is particularly concerning given that populations who use safety-net health systems have already experienced barriers in timely access to health care even before the onset of the COVID-19 pandemic.…”
ImportanceSurveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is underused. Identifying potentially modifiable factors to address barriers in HCC surveillance is critical to improve patient outcomes.ObjectiveTo evaluate clinician-level factors contributing to underuse of HCC surveillance in patients with cirrhosis.Design, Setting, and ParticipantsThis survey study included primary care clinicians (PCCs) and gastroenterology and hepatology clinicians at 5 safety-net health systems in the US. Clinicians were surveyed from March 15 to September 15, 2023, to assess knowledge, attitudes, beliefs, perceived barriers, and COVID-19–related disruptions in HCC surveillance in patients with cirrhosis. Data were analyzed from October to November 2023.Main Outcome and MeasuresHCC surveillance knowledge was assessed with 6 questions querying the respondent’s ability to correctly identify appropriate use of HCC surveillance. Attitudes, perceived barriers, and beliefs regarding HCC surveillance and perceived impact of the COVID-19 pandemic–related disruptions with HCC surveillance were assessed with a series of statements using a 4-point Likert scale and compared PCCs and gastroenterology and hepatology clinicians.ResultsOverall, 347 of 1362 clinicians responded to the survey (25.5% response rate), among whom 142 of 237 (59.9%) were PCCs, 48 of 237 (20.3%) gastroenterology and hepatology, 190 of 236 (80.5%) were doctors of medicine and doctors of osteopathic medicine, and 46 of 236 (19.5%) were advanced practice clinicians. On HCC knowledge assessment, 144 of 270 (53.3%) scored 5 or more of 6 questions correctly, 37 of 48 (77.1%) among gastroenterology and hepatology vs 65 of 142 (45.8%) among PCCs (P < .001). Those with higher HCC knowledge scores were less likely to report barriers to HCC surveillance. PCCs were more likely to report inadequate time to discuss HCC surveillance (37 of 139 [26.6%] vs 2 of 48 [4.2%]; P = .001), difficulty identifying patients with cirrhosis (82 of 141 [58.2%] vs 5 of 48 [10.4%]; P < .001), and were not up-to-date with HCC surveillance guidelines (87 of 139 [62.6%] vs 5 of 48 [10.4%]; P < .001) compared with gastroenterology and hepatology clinicians. While most acknowledged delays during the COVID-19 pandemic, 62 of 136 PCCs (45.6%) and 27 of 45 gastroenterology and hepatology clinicians (60.0%) reported that patients with cirrhosis could currently complete HCC surveillance without delays.Conclusions and RelevanceIn this survey study, important gaps in knowledge and perceived barriers to HCC surveillance were identified. Effective delivery of HCC education to PCCs and health system–level interventions must be pursued in parallel to address the complex barriers affecting suboptimal HCC surveillance in patients with cirrhosis.
“…Most clinicians reported that patients with cirrhosis often missed appointments and HCC surveillance was delayed due to limitations of in-person visits. These observations confirm existing reports and concerns about the long-term outcomes of delays in cirrhosis care following onset of the COVID-19 pandemic . However, even more concerning, among survey respondents in the current study, it is clear that despite being over 3 years post onset of the pandemic, the disruptions in cirrhosis care and HCC surveillance in particular remain, and most respondents do not have an effective mechanism to track and re-engage patients who missed HCC surveillance during the pandemic.…”
Section: Discussionsupporting
confidence: 74%
“…These observations confirm existing reports and concerns about the long-term outcomes of delays in cirrhosis care following onset of the COVID-19 pandemic. [33][34][35] However, even more concerning, among survey respondents in the current study, it is clear that despite being over 3 years post onset of the pandemic, the disruptions in cirrhosis care and HCC surveillance in particular remain, and most respondents do not have an effective mechanism to track and re-engage patients who missed HCC surveillance during the pandemic. This is particularly concerning given that populations who use safety-net health systems have already experienced barriers in timely access to health care even before the onset of the COVID-19 pandemic.…”
ImportanceSurveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is underused. Identifying potentially modifiable factors to address barriers in HCC surveillance is critical to improve patient outcomes.ObjectiveTo evaluate clinician-level factors contributing to underuse of HCC surveillance in patients with cirrhosis.Design, Setting, and ParticipantsThis survey study included primary care clinicians (PCCs) and gastroenterology and hepatology clinicians at 5 safety-net health systems in the US. Clinicians were surveyed from March 15 to September 15, 2023, to assess knowledge, attitudes, beliefs, perceived barriers, and COVID-19–related disruptions in HCC surveillance in patients with cirrhosis. Data were analyzed from October to November 2023.Main Outcome and MeasuresHCC surveillance knowledge was assessed with 6 questions querying the respondent’s ability to correctly identify appropriate use of HCC surveillance. Attitudes, perceived barriers, and beliefs regarding HCC surveillance and perceived impact of the COVID-19 pandemic–related disruptions with HCC surveillance were assessed with a series of statements using a 4-point Likert scale and compared PCCs and gastroenterology and hepatology clinicians.ResultsOverall, 347 of 1362 clinicians responded to the survey (25.5% response rate), among whom 142 of 237 (59.9%) were PCCs, 48 of 237 (20.3%) gastroenterology and hepatology, 190 of 236 (80.5%) were doctors of medicine and doctors of osteopathic medicine, and 46 of 236 (19.5%) were advanced practice clinicians. On HCC knowledge assessment, 144 of 270 (53.3%) scored 5 or more of 6 questions correctly, 37 of 48 (77.1%) among gastroenterology and hepatology vs 65 of 142 (45.8%) among PCCs (P < .001). Those with higher HCC knowledge scores were less likely to report barriers to HCC surveillance. PCCs were more likely to report inadequate time to discuss HCC surveillance (37 of 139 [26.6%] vs 2 of 48 [4.2%]; P = .001), difficulty identifying patients with cirrhosis (82 of 141 [58.2%] vs 5 of 48 [10.4%]; P < .001), and were not up-to-date with HCC surveillance guidelines (87 of 139 [62.6%] vs 5 of 48 [10.4%]; P < .001) compared with gastroenterology and hepatology clinicians. While most acknowledged delays during the COVID-19 pandemic, 62 of 136 PCCs (45.6%) and 27 of 45 gastroenterology and hepatology clinicians (60.0%) reported that patients with cirrhosis could currently complete HCC surveillance without delays.Conclusions and RelevanceIn this survey study, important gaps in knowledge and perceived barriers to HCC surveillance were identified. Effective delivery of HCC education to PCCs and health system–level interventions must be pursued in parallel to address the complex barriers affecting suboptimal HCC surveillance in patients with cirrhosis.
The number of cancer cases diagnosed during the coronavirus disease 2019 (COVID-19) pandemic has decreased. This study investigated the impact of the pandemic on the clinical practice of hepatocellular carcinoma (HCC) using a novel nationwide REgistry for Advanced Liver diseases (REAL) in Japan. We retrieved data of patients initially diagnosed with HCC between January 2018 and December 2021. We adopted tumor size as the primary outcome measure and compared it between the pre-COVID-19 (2018 and 2019) and COVID-19 eras (2020 and 2021). We analyzed 13,777 patients initially diagnosed with HCC (8074 in the pre-COVID-19 era and 5703 in the COVID-19 era). The size of the maximal intrahepatic tumor did not change between the two periods (mean [SD] = 4.3 [3.6] cm and 4.4 [3.6] cm), whereas the proportion of patients with a single tumor increased slightly from 72.0 to 74.3%. HCC was diagnosed at a similar Barcelona Clinic Liver Cancer stage. However, the proportion of patients treated with systemic therapy has increased from 5.4 to 8.9%. The proportion of patients with a non-viral etiology significantly increased from 55.3 to 60.4%. Although the tumor size was significantly different among the etiologies, the subgroup analysis showed that the tumor size did not change after stratification by etiology. In conclusion, the characteristics of initially diagnosed HCC remained unchanged during the COVID-19 pandemic in Japan, regardless of differences in etiology. A robust surveillance system should be established particularly for non-B, non-C etiology to detect HCC in earlier stages.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.